Chemical formula: C₅₂H₈₈N₁₀O₁₅ Molecular mass: 1,093.331 g/mol PubChem compound: 3035406
Caspofungin is indicated for:
Population group: only adults (18 years old or older)
Treatment of invasive candidiasis in adult patients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Treatment of invasive candidiasis in adult or paediatric patients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Treatment of invasive aspergillosis in paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult patients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic paediatric patients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
